Prognostic Utility of Molecular Classification in Skull Base Meningiomas Treated with Stereotactic Radiosurgery
Journal of Neurological Surgery Part B: Skull Base · 13.10.2026
DOI: 10.1055/a-2971-9751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 13.10.2026. Verfasst von Motoyuki Umekawa und 16 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Molecular analysis has emerged as a prognostic tool for meningiomas; however, its impact on outcomes following stereotactic radiosurgery (SRS) in skull base meningiomas remains unclear. This is a retrospective study of patients with surgically resected skull base meningiomas followed by SRS between 1999 and 2023. Tumors were categorized into three molecular groups using whole-exome sequencing (WES): Group A (NF2-wildtype), Group B (NF2-mutant/22q loss), and Group C (TERT promoter mutation or high-risk copy number alterations [CNAs]). The primary outcome was progression-free survival (PFS) rates, and the secondary outcome was disease-specific survival (DSS) rates. A total of 75 skull base meningiomas in 73 patients were included in this study (median age, 60 years; follow-up after SRS, 45 months; prescription dose, 16 Gy; 64% female), with predominant diagnosis of World Health Organization (WHO) grade 1 (58 tumors). After WES, 34 tumors were molecularly classified for Group A, 11 for Group B, and 30 for Group C. Group C exhibited significantly poorer PFS at 5 years (50%; vs. A 87%, p < 0.001; and B 100%, p = 0.008: log-rank test), and poorer DSS at 10 years (50%; vs. A 100%, p < 0.001; and B 100%, p = 0.014). In Cox proportional hazards analysis, Group C (vs. A/B) and tumor volume were significantly associated with tumor progression after SRS, while WHO grade and tumor location were not. Molecular profiling revealed that skull base meningiomas with high-risk CNAs experience significantly worse outcomes after SRS, implying potentially individualized strategies in this traditionally favorable subgroup.
Förderung
- JSPS KAKENHI
Zitieren
APA
Umekawa, M., Shinya, Y., Hirano, Y., Miyawaki, S., Hasegawa, H., Sakai, Y., Teranishi, Y., Ogawa, S., Hirata, T., Katano, A., Komura, D., Katoh, H., Ikemura, M., Ono, H., Ushiku, T., Ishikawa, S., & Saito, N. (2026). Prognostic Utility of Molecular Classification in Skull Base Meningiomas Treated with Stereotactic Radiosurgery. Journal of Neurological Surgery Part B: Skull Base. https://doi.org/10.1055/a-2971-9751
Vancouver
Umekawa M, Shinya Y, Hirano Y, Miyawaki S, Hasegawa H, Sakai Y, et al. Prognostic Utility of Molecular Classification in Skull Base Meningiomas Treated with Stereotactic Radiosurgery. Journal of Neurological Surgery Part B: Skull Base. 2026. doi:10.1055/a-2971-9751
BibTeX
@article{Umekawa2026,
author = {Umekawa, Motoyuki and Shinya, Yuki and Hirano, Yudai and Miyawaki, Satoru and Hasegawa, Hirotaka and Sakai, Yu and Teranishi, Yu and Ogawa, Shotaro and Hirata, Takeru and Katano, Atsuto and Komura, Daisuke and Katoh, Hiroto and Ikemura, Masako and Ono, Hideaki and Ushiku, Tetsuo and Ishikawa, Shumpei and Saito, Nobuhito},
title = {Prognostic Utility of Molecular Classification in Skull Base Meningiomas Treated with Stereotactic Radiosurgery},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2026},
doi = {10.1055/a-2971-9751}
}
EUVIMED